-
Mashup Score: 6
In a phase II trial (Alliance A091802) reported in the Journal of Clinical Oncology, Zandberg et al investigated the survival benefit of adding cetuximab to avelumab in patients with advanced cutaneou…
Source: ascopost.comCategories: General Medicine NewsTweet
-
Mashup Score: 9Chronicling the Extraordinary Career of Stephen R. Grobmyer, MD, FACS, in Breast Cancer Research, Surgery, and Treatment - 9 day(s) ago
In this installment of The ASCO Post’s Living a Full Life series, Stephen R. Grobmyer, MD, FACS, speaks about his clinical and research career in oncology, the challenges and rewards of moving to Abu …
Source: ascopost.comCategories: General Medicine NewsTweet-
It was my pleasure to talk to my friend and colleague @grobmys https://t.co/uxZxPyj9oN @CCAD @CleClinicMD Remarkable journey of improving cancer care in the US and globally !! https://t.co/ZXqQB5tG4V
-
-
Mashup Score: 6Revumenib in Triplet Regimen Under Study in Newly Diagnosed AML With NPM1/KMT2A Alterations - 10 day(s) ago
A new combination of azacitidine, venetoclax, and revumenib demonstrated high rates of complete response and clinical activity in older adults with newly diagnosed acute myeloid leukemia and an NPM1 m…
Source: ascopost.comCategories: General Medicine NewsTweet-
Leading the ongoing trial in older adults with NPM1-mutant or KMT2A-rearranged AML, @LeukDocJZ reports the addition of oral revumenib to azacitidine + venetoclax is safe and drives high remission rates, paving the way for a pivotal phase III. #AML https://t.co/wL8Ue3JPbt https://t.co/8CFDJugzNV
-
-
Mashup Score: 26FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable, Locally Advanced Head and Neck Cancer - 11 day(s) ago
The FDA approved pembrolizumab (Keytruda) for adults with resectable, locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 [combined positive score ≥ 1] as determined by a…
Source: ascopost.comCategories: General Medicine NewsTweet-
FDA approves pembrolizumab for resectable, locally advanced HNSCC based on KEYNOTE‑689. Led by Dr. Ravindra Uppaluri @DrUppaluri, the study showed a 30% drop in recurrence risk. Full details from The ASCO Post: https://t.co/ZLzVPI9Jn5 #HNSCC #Oncology https://t.co/si0lci0hBP
-
-
Mashup Score: 4
In a phase III trial (OASIS-4) reported at the 2025 Annual ASCO Meeting and in the New England Journal of Medicine, Cardoso et al attempted to determine whether the neurokinin-targeted therapy elinzan…
Source: ascopost.comCategories: General Medicine NewsTweet-
Elinzanetant (OASIS‑4) cut hot flash frequency by ~3 episodes/day at week 4 vs placebo in HR‑positive breast cancer patients on endocrine therapy.@DrSGraff led the study; Dr Christian Rommel #ChristianRommel, highlighted its potential for adherence. https://t.co/OkkvaDNswx
-
-
Mashup Score: 3Alicia K. Morgans, MD, MPH, FASCO, on How Does Androgen Receptor Inhibition Affect Quality of Life? - 14 day(s) ago
Alicia K. Morgans, MD, MPH, FASCO, of Dana-Farber Cancer Institute, discusses health-related quality-of-life data from the phase III ARAN OTE trial, which evaluated the androgen receptor inhibitor darolutamide in combination with androgen-deprivation therapy (ADT) vs ADT plus placebo for patients with metastatic hormone-sensitive prostate cancer (Abstract 5004). Disclaimer: This video transcript has not been proofread or edited and may contain errors. On behalf of the ARASENS investigators, I was very
Source: ascopost.comCategories: General Medicine NewsTweet-
From #ASCO25: Dr. Alicia Morgans @CaPsurvivorship discusses health-related quality-of-life data from the phase III ARANOTE trial https://t.co/ImUXViqgf4
-
-
Mashup Score: 1
In a phase III trial (C-POST) reported at the 2025 ASCO Annual Meeting and in The New England Journal of Medicine, Rischin et al compared disease-free survival outcomes of adjuvant cemiplimab vs place…
Source: ascopost.comCategories: General Medicine NewsTweet-
New data from the C-POST Phase 3 trial show adjuvant cemiplimab (Libtayo) significantly improves disease-free survival in high-risk cutaneous squamous cell carcinoma. Presented by Dr. Danny Rischin at #ASCO2025. Explore the findings: https://t.co/zf9pHMmyBF https://t.co/iTXGZJM5OR
-
-
Mashup Score: 5
With the currently available BCR::ABL1 tyrosine kinase inhibitors, chronic myeloid leukemia (CML) has transformed from an invariably fatal disorder (10-year overall survival < 10%) to an indolent o…
Source: ascopost.comCategories: General Medicine NewsTweet-
Low-cost dasatinib from Mark Cuban’s Cost Plus may reshape CML therapy. As Kantarjian, Paul, and Haddad note, cost is a growing factor in #Hematology and #Oncology decisions. https://t.co/qyGqTjghCX https://t.co/UPtgKDL6bZ
-
-
Mashup Score: 10Novel Antibody-Drug Conjugate for Newly Diagnosed BPDCN - 16 day(s) ago
A first-in-class antibody-drug conjugate was found to be safe and effective for patients with blastic plasmacytoid dendric cell neoplasm (BPDCN), according to data from a phase I/II study.
Source: ascopost.comCategories: General Medicine NewsTweet-
👉Novel Antibody-Drug Conjugate for Newly Diagnosed #BPDCN - The ASCO Post @ASCOPost @doctorpemm @Daver_Leukemia @MDAndersonNews | #ASCO25 #endcancer https://t.co/XcLiyOCMJi
-
-
Mashup Score: 38Novel Antibody-Drug Conjugate for Newly Diagnosed BPDCN - 17 day(s) ago
A first-in-class antibody-drug conjugate was found to be safe and effective for patients with blastic plasmacytoid dendric cell neoplasm (BPDCN), according to data from a phase I/II study.
Source: ascopost.comCategories: General Medicine NewsTweet-
Thanks 🙏 to @ASCOPost @ASCO for featuring our #Pivekimab #PVEK #CD123 for #BPDCN program | @doctorpemm @Daver_Leukemia @MDAndersonNews | #endcancer https://t.co/XkXdoCAYCr https://t.co/f2uLdn63ME
-
Avelumab + cetuximab showed promising activity in advanced cutaneous SCC in a phase II trial led by Dr. Shailender Bhatia and colleagues. Details on ORR, DOR, and more: 🔗 https://t.co/hFzrwVm2Kx #CutaneousSCC #Immunotherapy https://t.co/ce3eqioIPJ